BiotechTube

Placebo + ALN-APP

Phase 2Recruiting
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cerebral Amyloid Angiopathy

Conditions

Cerebral Amyloid Angiopathy

Trial Timeline

May 17, 2024 → Dec 14, 2029

NCT ID
NCT06393712

About Placebo + ALN-APP

Placebo + ALN-APP is a phase 2 stage product being developed by Alnylam Pharmaceuticals for Cerebral Amyloid Angiopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06393712. Target conditions include Cerebral Amyloid Angiopathy.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06393712Phase 2Recruiting

Competing Products

20 competing products in Cerebral Amyloid Angiopathy

See all competitors
ProductCompanyStageHype Score
mouse nerve growth factorSun PharmaceuticalApproved
85
Edaravone Dexborneol + PlaceboSun PharmaceuticalPhase 2
52
Oral Glycopyrrolate LiquidShionogiPhase 3
77
recombinant human erythropoietin alfa + 0.9% NaClJohnson & JohnsonPhase 2/3
65
UDI-001Rohto PharmaceuticalPhase 1/2
41
NXY-059AstraZenecaPhase 3
77
NXY-059AstraZenecaPhase 2
52
RosuvastatinAstraZenecaApproved
85
NXY-059AstraZenecaPhase 3
77
Comparator: Placebo + Comparator: MK0724MerckPhase 2
52
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mgMerckPhase 2
52
Recombinant Factor VIIa + Biological/Vaccine: PlaceboNovo NordiskPhase 3
76
Recombinant Activated Factor VII (rFVIIa) + PlaceboNovo NordiskPhase 3
76
PonezumabPfizerPhase 2
51
PF-05230907PfizerPhase 1
32
Azithromycin + Pyrimethamine + Leucovorin calciumPfizerPhase 1
32
clopidogrel (SR25990C)SanofiApproved
84
Intrarectal quinineSanofiPhase 3
76
PiracetamUCBApproved
82
CN-105Tiantan BioPhase 2
49

Other Products from Alnylam Pharmaceuticals

PatisiranPhase 3
74
PatisiranPhase 3
74
Givosiran + PlaceboPhase 3
74
Nucresiran + Sterile Normal Saline (0.9% NaCl)Phase 3
74
LumasiranPhase 3
74